Commission Regulation (EC) No 1530/2002 of 27 August 2002 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance)
Date: 2002-08-27
Institutions: European Commission
Subjects: animal product, food processing, foodstuffs legislation, health policy, pharmaceutical product, veterinary drug

28.8.2002

EN

Official Journal of the European Communities

L 230/3

COMMISSION REGULATION (EC) No 1530/2002

of 27 August 2002

amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community
procedure for the establishment of maximum residue limits of veterinary medicinal products in
foodstuffs of animal origin

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European
Community,

Having regard to Council Regulation (EEC) No 2377/90 of 26
June 1990 laying down a Community procedure for the estab-
lishment of maximum residue limits of veterinary medicinal
products in foodstuffs of animal origin (1), as last amended by
Commission Regulation (EC) No 1181/2002 (2), and in parti-
cular Articles 6, 7 and 8 thereof;

Whereas:

(1)

(2)

(3)

(4)

(5)

In accordance with Regulation (EEC) No 2377/90,
maximum residue limits must be established progres-
sively for all pharmacologically active substances which
are used within the Community in veterinary medicinal
products intended for administration to food-producing
animals.

Maximum residue limits should be established only after
the examination within the Committee for Veterinary
information
Medicinal Products of all
the substance
concerning the safety of
foodstuffs of animal
concerned for the consumer of
origin and the impact of residues on the industrial
processing of foodstuffs.

the relevant

residues of

In establishing maximum residue limits for residues of
veterinary medicinal products in foodstuffs of animal
origin,
it is necessary to specify the animal species in
which residues may be present, the levels which may be
present in each of the relevant meat tissues obtained
from the treated animal (target tissue) and the nature of
the residue which is relevant for the monitoring of resi-
dues (marker residue).

In view of the reduced availability of veterinary medic-
for certain food-producing species (3),
inal products
maximum residue limits may be established by methods
of extrapolation from maximum residue limits set for
other species on a strictly scientific basis.

For the control of residues, as provided for in appro-
priate Community legislation, maximum residue limits
should usually be established for the target tissues of
liver or kidney. However,
the liver and kidney are
frequently removed from carcasses moving in interna-

(1) OJ L 224, 18.8.1990, p. 1.
(2) OJ L 172, 2.7.2002, p. 13.
(3) Communication from the Commission to the European Parliament
and to the Council on availability of veterinary medicinal products
(COM(2000) 806 final).

(6)

(7)

(8)

(9)

tional trade, and maximum residue limits should there-
fore also always be established for muscle or fat tissues.

In the case of veterinary medicinal products intended for
use in laying birds,
lactating animals or honey bees,
maximum residue limits must also be established for
eggs, milk or honey.

Streptomycin and Meloxicam
Dihydrostreptomycin,
should be inserted into Annex I to Regulation (EEC) No
2377/90.

Azagly-nafarelin and Deslorelin acetate
inserted into Annex II to Regulation (EEC) No 2377/90.

should be

In order to allow for the completion of scientific studies,
the duration of the validity of the provisional maximum
residue limits previously defined in Annex III to Regula-
tion (EEC) No 2377/90 should be extended for Altreno-
gest.

(10) An adequate period should be allowed before the entry
into force of this Regulation in order to allow Member
States to make any adjustment which may be necessary
to the authorisations to place the veterinary medicinal
products concerned on the market which have been
granted in accordance with Directive 2001/82/EC of the
European Parliament and of
to take
account of the provisions of this Regulation.

the Council (4)

(11)

The measures provided for in this Regulation are in
accordance with the opinion of the Standing Committee
on Veterinary Medicinal Products,

HAS ADOPTED THE FOLLOWING REGULATION:

Article 1

Annexes I,
hereby amended as set out in the Annex hereto.

II and III to Regulation (EEC) No 2377/90 are

Article 2

This Regulation shall enter into force on the third day following
its publication in the Official Journal of the European Communities.

It shall apply from the 60th day following its publication.

(4) OJ L 311, 28.11.2001, p. 1.

L 230/4

EN

Official Journal of the European Communities

28.8.2002

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 27 August 2002.

For the Commission

Erkki LIIKANEN

Member of the Commission

A. Annex I to Regulation (EEC) No 2377/90 is amended as follows:

ANNEX

1.

1.2.

Anti-infectious agents

Antibiotics

1.2.10. Aminoglycosides

Pharmacologically active
substance(s)

Marker residue

Animal species

MRLs

Target tissues

Other provisions

‘Dihydrostreptomycin

Dihydrostreptomycin

Bovine, ovine

Porcine

Streptomycin

Streptomycin

Bovine, ovine

Porcine

500 µg/kg
500 µg/kg
500 µg/kg
1 000 µg/kg
200 µg/kg

500 µg/kg
500 µg/kg
500 µg/kg
1 000 µg/kg

500 µg/kg
500 µg/kg
500 µg/kg
1 000 µg/kg
200 µg/kg

500 µg/kg
500 µg/kg
500 µg/kg
1 000 µg/kg

Muscle
Fat
Liver
Kidney
Milk

Muscle
Skin and fat
Liver
Kidney

Muscle
Fat
Liver
Kidney
Milk

Muscle
Skin and fat
Liver
Kidney’

4.

Anti-inflammatory agents

4.1.

Non-steroidal anti-inflammatory agents

4.1.3.

Enolic acid derivates

Pharmacologically active
substance(s)

Marker residue

Animal species

MRLs

Target tissues

Other provisions

‘Meloxicam

Meloxicam

Equidae

20 µg/kg
65 µg/kg
65 µg/kg

Muscle
Liver
Kidney’

.

.

2
8
8
2
0
0
2

E
N

O

f
f
i
c
i
a
l

J
o
u
r
n
a
l

o
f

t
h
e

E
u
r
o
p
e
a
n
C
o
m
m
u
n
i
t
i
e
s

L

2
3
0
/
5

B. Annex II to Regulation (EEC) No 2377/90 is amended as follows:

2.

Organic compounds

Pharmacologically active substance(s)

Animal species

Other provisions

‘Azagly-nafarelin

Deslorelin acetate

Salmonidae

Equidae

C. Annex III to Regulation (EEC) No 2377/90 is amended as follows:

Not for use in fish from which eggs are produced for human
consumption’

6.

6.1.

Agents acting on the reproductive system

Progestogens

Pharmacologically active
substance(s)

Marker residue

Animal species

MRLs

Target tissues

Other provisions

‘Altrenogest

Altrenogest

Porcine

Equidae

3 µg/kg
3 µg/kg
3 µg/kg

3 µg/kg
3 µg/kg
3 µg/kg

Skin and fat
Liver
Kidney

Fat
Liver
Kidney

Provisional MRLs expire on 1.1.2005; for zootech-
nical use only’

L

2
3
0
/
6

E
N

O

f
f
i
c
i
a
l

J
o
u
r
n
a
l

o
f

t
h
e

E
u
r
o
p
e
a
n
C
o
m
m
u
n
i
t
i
e
s

.

.

2
8
8
2
0
0
2